Supply bottlenecks, new competitors and introductory pricing may shift healthcare dependence rather than simply reduce costs.

ADHD stimulants — Adderall, Vyvanse, Concerta — are Schedule II controlled substances. The DEA sets an annual Aggregate Production Quota, a hard national ceiling on how much active ingredient can be manufactured. If demand exceeds the quota, manufacturers cannot legally produce more, even with raw materials and factory capacity available. Adderall and methylphenidate ER remain on the FDA Drug Shortage Database as of July 2026. The DEA raised 2026 quotas, but higher quotas do not translate instantly into pharmacy shelves. Equilibrium is not projected until late 2026 at earliest.

For UK patients, Elvanse (lisdexamfetamine — the British name for Vyvanse, made by Takeda) and Concerta XL shortages have persisted since late 2023, constituting what official NHS data describes as a structural crisis affecting hundreds of thousands. For US patients, Adderall XR and generic methylphenidate ER remain on the FDA shortage list. Missing a month of stimulant medication is not an inconvenience. For adults with ADHD, it can mean job performance collapse, missed deadlines, and loss of income. The cost is not priced into any official statistic.

The Law of the Trap: a system is built with just enough dysfunction to keep people dependent and just enough compliance theatre to prevent revolt. The DEA raising quotas by 14 to 22 percent generates headlines that feel like progress. The structural formula that caused the shortage — a backward-looking model calibrated to prior-year consumption rather than rising diagnostic rates — remains unchanged. People feel grateful for the increase. They were supposed to. The trap is not the shortage. The trap is the architecture that makes the shortage permanent.

Sciwind Biosciences received Chinese regulatory approval for ecnoglutide, its own GLP-1 drug, in 2026, immediately partnering with Pfizer's China division for commercialisation. Semaglutide's patent expires in China in 2026, earlier than in any major developed market. Novo Nordisk CEO Mike Doustdar admitted China was the single underperforming region in an otherwise strong global earnings report — Ozempic sales fell 5 percent in China last year, the first decline since its 2021 Chinese approval. A pipeline of domestic Chinese GLP-1 manufacturers, including Hengrui and Hansoh Pharmaceutical, are advancing assets with ambitions beyond the domestic market.

For UK and US investors holding Novo Nordisk stock — which has already corrected significantly from 2024 highs — the China development is a second-order price signal that has not fully landed. GLP-1 therapies generated approximately $132 billion in global sales in 2025. China is the fastest-growing regional market. If domestic Chinese competition compresses Novo Nordisk's China revenue while simultaneously developing export-grade biosimilars, the western duopoly valuation model breaks. Novo Nordisk's share price already reflects a premium for monopoly pricing power. That premium is now structurally vulnerable.

The Law of the Narcissist: the dominant player mistakes its own success for the permanent shape of the world. Novo Nordisk built a $132 billion market and assumed the moat was the molecule. The moat was always the patent. In China, that moat expires in 2026. Western financial media is still covering the GLP-1 story as a Novo versus Lilly story. The country rewriting the competitive map is not in that frame. When you believe you are the centre of the story, you do not see the flanking move until the revenue line turns.

Eli Lilly's oral GLP-1 pill, orforglipron, reached the US market in April 2026, priced at $149 per month — undercutting Novo Nordisk's oral Wegovy by $50 to $150 depending on dose. Medicare coverage, launched July 2026, brought the cost for eligible seniors to $50 per month. Gallup data shows 12.4 percent of US adults are now on GLP-1 drugs, more than double the rate from February 2024. Lilly simultaneously secured tariff relief and FDA fast-track incentives as part of its government pricing deal. The global GLP-1 market is valued at $52.3 billion in 2026 and projected to reach $97.45 billion by 2031.

Eli Lilly guided full-year 2026 revenue of $80 to $83 billion. Tirzepatide products generated over $62 billion in combined 2025 sales alone. Starting July 1, 2026, Medicare beneficiaries access GLP-1 obesity drugs at $50 per month — the first time Medicare has ever covered obesity treatment. The Congressional Budget Office previously estimated that expanding Medicare GLP-1 coverage could increase federal spending by tens of billions of dollars over a decade. Lilly, in exchange, received tariff relief and expedited FDA review incentives. The price cut is real. The structural beneficiary is Lilly.

The Law of the Addict: once the body is on a drug, the demand is no longer voluntary. GLP-1 medications suppress appetite through a biological mechanism — stopping the drug triggers appetite rebound. This is not a moral failing. It is pharmacology. The $149 price point and Medicare coverage are designed to maximise the number of people who start. The market is not $52 billion because the drugs work. It is $52 billion because the drugs work and they cannot be stopped. The entry price is the marketing. The lifetime subscription is the business model.